Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancerBhuvaneswari Ramaswamy, William E. Carson, Rachel M. Layman et al.|Cancer Research|2016Cited by 15
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Bhuvaneswari Ramaswamy, H. Boutrid et al.|Breast Cancer Research and Treatment|2024Cited by 12